INSIGHTS ON CONTRACT PHARMA MANUFACTURING

• How IntegriCell™ Services In Belgium Ensure Cell Viability, Supply Chain Integrity

  he effectiveness of cell-based therapies hinges on preserving cell viability, stability, and consistency. However, inconsistencies in cryopreservation methods have undermined therapeutic success.

• Enabling The Outcome Through Enhancing Patient Accessibility

  To ensure that the transformative potential of cell and gene therapy reaches every patient in need, we must prioritize equitable access and overcome the remaining barriers to widespread delivery.

• How BioServices Centers In France Enable Efficiency And Scalability

  To support the growing demands of the ATMP industry, it's essential to leverage integrated biostorage, sample management, and regulatory solutions, and we are committed to enhancing these capabilities.

• 5 Steps To Design A Microbiological Performance Qualification For Facilities Explore five steps to design an EMPQ for sterile manufacturing: classification, protocol drafting, cleaning evaluation, disinfectant efficacy testing, and continuous improvement.
• Early-Phase Whole-Body PK

  Accelerate your path to the clinic with Aliri’s cost-effective, label-free whole-body PK service — designed to deliver deeper insights, faster decisions, and better outcomes for your drug candidates.

• Label-Free Whole-Body Pharmacokinetics

  This approach enables tissue-level analysis, delivering insights into efficacy at the site of action, uncovering potential safety concerns, and supporting smarter clinical candidate selection.

• What Is Causing Limited Bioavailability

  Discover how this label-free whole-body QMSI combined with plasma LC-MS/MS can help identify the root causes of limited bioavailability and guide smarter optimization strategies early in development.

• Time: A Crucial Factor In Therapeutics Development

  Accelerate your mRNA development and strengthen your response to emerging health threats with next-generation, cell-free DNA template solutions designed for speed, quality, and reliability.

• Spray Dried Dispersions: Performance, Manufacturability, Stability

  Explore advanced approaches to designing robust amorphous formulations and optimizing spray drying processes tailored specifically to difficult-to-formulate compounds.

• Enabling mRNA Therapeutic Development Through Enhanced IVT Capping Efficiency

  See how Codex HiCap RNA Polymerase supports the production of high-performance synthetic mRNA, paving the way for next-generation mRNA therapies.